06-JUL-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 171 34 0 0 0 08/13/2019 29 5
            1448 171 34 0 0 0      
 
    2 Y 1 Lenalidomide   674 86 21 4 0 0 08/13/2019    
        2 Lenalidomide + Daratumumab   664 83 22 4 2 1      
            1338 169 43 8 2 1      
 
    3 Y 3 Stop vs Continue Treatment   274 84 47 17 2 1 08/13/2019    
            274 84 47 17 2 1      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 8 7 2 2 0 0 01/05/2022 110 28
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   6 3 1 1 0 0      
            15 10 3 3 0 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 29 19 9 4 0 0 10/12/2023 259 82
        2 DRD-R   30 20 10 5 3 1      
        3 DRD-DR   26 17 8 4 1 0      
            85 56 27 13 4 1      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 14 13 7 3 0 0 07/01/2024 145 43
            14 13 7 3 0 0      
 
    2 Y 1 Dara-VCD   4 4 3 2 1 0 07/01/2024    
        2 Melphalan + ASCT   4 4 3 2 1 0      
            8 8 6 4 2 0      
 
    3 Y 3 Dara   1 1 1 0 0 0 07/01/2024    
            1 1 1 0 0 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   56 10 6 3 2 0 05/27/2021 229 79
            56 10 6 3 2 0      
 
    1 E Total Registrations   42 7 5 3 2 1 05/27/2021    
            42 7 5 3 2 1      
 
    2 E Total Registrations   30 9 2 1 1 0 05/27/2021    
            30 9 2 1 1 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   78 10 3 3 2 1 01/08/2020 252 100
            78 10 3 3 2 1      
 
    1 E Total Registrations   38 6 1 1 1 1 01/08/2020    
            38 6 1 1 1 1      
 

06-JUL-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 110 28